Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Post Quarterly Sales of $9.47 Million

Brokerages expect Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) to announce $9.47 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Nabriva Therapeutics’ earnings. The lowest sales estimate is $8.53 million and the highest is $10.40 million. Nabriva Therapeutics reported sales of $8.24 million in the same quarter last year, which indicates a positive year-over-year growth rate of 14.9%. The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Nabriva Therapeutics will report full year sales of $41.31 million for the current fiscal year, with estimates ranging from $39.32 million to $43.29 million. For the next fiscal year, analysts expect that the company will report sales of $71.73 million, with estimates ranging from $67.25 million to $76.21 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Nabriva Therapeutics had a negative return on equity of 82.07% and a negative net margin of 137.52%. During the same quarter last year, the business earned ($0.53) EPS.

A number of research analysts have recently issued reports on NBRV shares. Northland Securities dropped their price objective on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 30th. Zacks Investment Research cut shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 11th. Finally, StockNews.com assumed coverage on shares of Nabriva Therapeutics in a report on Sunday. They set a “hold” rating on the stock.

NASDAQ NBRV opened at $0.19 on Wednesday. The firm has a market capitalization of $120.59 million, a price-to-earnings ratio of -0.20 and a beta of 1.57. The company has a current ratio of 4.01, a quick ratio of 2.94 and a debt-to-equity ratio of 0.09. Nabriva Therapeutics has a 1 year low of $0.18 and a 1 year high of $2.32. The firm’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.52.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. FMR LLC boosted its holdings in Nabriva Therapeutics by 77.0% during the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock valued at $7,958,000 after acquiring an additional 1,418,800 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Nabriva Therapeutics during the 1st quarter worth $179,000. GSA Capital Partners LLP acquired a new position in Nabriva Therapeutics during the 4th quarter valued at about $214,000. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics by 116.3% in the fourth quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 253,415 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Nabriva Therapeutics during the fourth quarter worth about $125,000. Institutional investors own 1.55% of the company’s stock.

About Nabriva Therapeutics (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

See Also

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Want More Great Investing Ideas?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.